Experimental pill combo takes on tough leukemia
NCT ID NCT05287568
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing two oral drugs, CC-486 and venetoclax, together in people with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment. The main goal is to find the safest dose of CC-486 when combined with venetoclax, and to monitor side effects. Up to 35 participants will take part in this open-label study at a single center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC-486 (oral azacitidine) and venetoclax
What this could lead to
If this works, it could offer a new treatment option for people with acute myeloid leukemia that has come back or not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 35 participants, so it is mainly checking safety and dosing. It may not lead to an effective treatment, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CU Anschutz Medical Campus
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact